Abstract
Chemotherapy is one of the major treatments of malignant carcinomas. However, its efficiency is affected by both intrinsic and acquired resistance to anticancer drugs. The cellular mechanisms of drug resistance include the overexpression of energy-dependent transporters that eject anticancer drugs from cells such as p-glycoprotein and multidrug resistance related protein (MRP), the mutation of drug targets, the activation of DNA repair pathways, the defects in cellular death pathways and so on. The genetic and epigenetic changes of these genes can lead to cancer drug resistance. Among these mechanisms, microRNAs (miRNAs) which are critical and essential for many important processes such as development, differentiation, and even carcinogenesis have been reported to regulate the chemo-sensitivity of tumor cells. In this paper we briefly review the relationship between miRNA and cancer drug resistance.
Similar content being viewed by others
References
Lippert T H, Ruoff H J, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung, 2008, 58: 261–264 18677966, 1:CAS:528:DC%2BD1cXpslKrsLw%3D
Biedler J L, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies. Cancer Res, 1970, 30: 1174–1184 5533992, 1:CAS:528:DyaE3cXktlelsrk%3D
Fojo T. Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat, 2007, 10: 59–67 17350322, 10.1016/j.drup.2007.02.002, 1:CAS:528:DC%2BD2sXkslahsbs%3D
Rodriguez A, Griffiths-Jones S, Ashurst J L, et al. Identification of mammalian microRNA host genes and transcription units. Genome Res, 2004, 14: 1902–1910 15364901, 10.1101/gr.2722704, 1:CAS:528:DC%2BD2cXotl2hu7w%3D
Zhao Y, Srivastava D. A developmental view of microRNA function. Trends Biochem Sci, 2007, 32: 189–197 17350266, 10.1016/j.tibs.2007.02.006, 1:CAS:528:DC%2BD2sXksFehsbc%3D
Bartel D P. microRNAs: Genomics, biogenesis, mechanism, and function. Cell, 2004, 116: 281–297 14744438, 10.1016/S0092-8674(04)00045-5, 1:CAS:528:DC%2BD2cXhtVals7o%3D
Griffiths-Jones S, Saini H K, van Dongen S, et al. miRBase: Tools for microRNA genomics. Nucleic Acids Res, 2008, 36(Database issue): D154–158 17991681, 1:CAS:528:DC%2BD1cXhtVWjsb8%3D
Caldas C, Brenton J D. Sizing up miRNAs as cancer genes. Nat Med, 2005, 11: 712–714 16015356, 10.1038/nm0705-712, 1:CAS:528:DC%2BD2MXmt1Wqtbo%3D
Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA, 2006, 103: 9136–9141 16754881, 10.1073/pnas.0508889103, 1:CAS:528:DC%2BD28XmsVWjsb8%3D
Calin G A, Sevignani C, Dumitru C D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 2004, 101: 2999–3004 14973191, 10.1073/pnas.0307323101, 1:CAS:528:DC%2BD2cXitlWhtr8%3D
Calin G A, Dumitru C D, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 2002, 99: 15524–15529 12434020, 10.1073/pnas.242606799, 1:CAS:528:DC%2BD3sXjvVOl
Cimmino A, Calin G A, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA, 2005, 102: 13944–13949 16166262, 10.1073/pnas.0506654102, 1:CAS:528:DC%2BD2MXhtVOqsbjK
Tricoli J V, Jacobson J W. microRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res, 2007, 67: 4553–4555 17510380, 10.1158/0008-5472.CAN-07-0563, 1:CAS:528:DC%2BD2sXltl2hurY%3D
Lu J, Getz G, Miska E A, et al. microRNA expression profiles classify human cancers. Nature, 2005, 435: 834–838 15944708, 10.1038/nature03702, 1:CAS:528:DC%2BD2MXkvVGgsLc%3D
Mitchell P S, Parkin R K, Kroh E M, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 2008, 105: 10513–10518 18663219, 10.1073/pnas.0804549105, 1:CAS:528:DC%2BD1cXpsVCltL0%3D
Blower P E, Verducci J S, Lin S, et al. microRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther, 2007, 6: 1483–1491 17483436, 10.1158/1535-7163.MCT-07-0009, 1:CAS:528:DC%2BD2sXotFalt7k%3D
Salter K H, Acharya C R, Walters K S, et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE, 2008, 3: e1908 18382681, 10.1371/journal.pone.0001908
Bertino J R, Banerjee D, Mishra P J. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics, 2007, 8: 1625–1627 18085993, 10.2217/14622416.8.12.1625, 1:CAS:528:DC%2BD2sXhsVCgs7zP
Mishra P J, Bertino J R. MicroRNA polymorphisms: The future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics, 2009, 10: 399–416 19290790, 10.2217/14622416.10.3.399, 1:CAS:528:DC%2BD1MXjtlOnsbk%3D
Brennecke J, Stark A, Russell R B, et al. Principles of microRNA-target recognition. PLoS Biol, 2005, 3: e85 15723116, 10.1371/journal.pbio.0030085
Saunders M A, Liang H, Li W H. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA, 2007, 104: 3300–3305 17360642, 10.1073/pnas.0611347104, 1:CAS:528:DC%2BD2sXjtVWltrs%3D
Lu J W, Gao C M, Wu J Z, et al. Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet, 2006, 51: 155–160 16424979, 10.1007/s10038-005-0339-4, 1:CAS:528:DC%2BD28Xis1Oktro%3D
Mishra P J, Humeniuk R, Mishra P J, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA, 2007, 104: 13513–13518 17686970, 10.1073/pnas.0706217104, 1:CAS:528:DC%2BD2sXps1ertr0%3D
To K K, Zhan Z, Litman T, et al. Regulation of ABCG2 expression at the 3′ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol, 2008, 28: 5147–5161 18573883, 10.1128/MCB.00331-08, 1:CAS:528:DC%2BD1cXhtVersL3N
Schulze-Bergkamen H, Krammer P H. Apoptosis in cancer-implications for therapy. Semin Oncol, 2004, 31: 90–119 14970941, 10.1053/j.seminoncol.2003.11.006, 1:CAS:528:DC%2BD2cXitVKrtr0%3D
Gupta A, Gartner J J, Sethupathy P, et al. Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nature, 2006, 442: 82–85 16738545, 1:CAS:528:DC%2BD28XmsFWntL0%3D
Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 2006, 130: 2113–2129 16762633, 10.1053/j.gastro.2006.02.057, 1:CAS:528:DC%2BD28XntVWit7g%3D
Si M L, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene, 2007, 26: 2799–2803 17072344, 10.1038/sj.onc.1210083, 1:CAS:528:DC%2BD2sXksF2rsb4%3D
Bussing I, Slack F J, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med, 2008, 14: 400–409 18674967, 10.1016/j.molmed.2008.07.001
Tsang W P, Kwok T T. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis, 2008, 13: 1215–1222 18758960, 10.1007/s10495-008-0256-z, 1:CAS:528:DC%2BD1cXhtFamsb%2FP
Yang H, Kong W, He L, et al. microRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 2008, 68: 425–433 18199536, 10.1158/0008-5472.CAN-07-2488, 1:CAS:528:DC%2BD1cXmt1Ontg%3D%3D
Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer, 2008, 123: 372–379 18449891, 10.1002/ijc.23501, 1:CAS:528:DC%2BD1cXnsF2jtrw%3D
Garofalo M, Quintavalle C, Di Leva G, et al. microRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 2008, 27(27): 3845–3855 18246122, 10.1038/onc.2008.6, 1:CAS:528:DC%2BD1cXntlCqu7k%3D
Miller T E, Ghoshal K, Ramaswamy B, et al. microRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(Kip1). J Biol Chem, 2008, 283: 29897–29903 18708351, 10.1074/jbc.M804612200, 1:CAS:528:DC%2BD1cXht1ynt7nI
Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun, 2008, 377: 114–119 18834855, 10.1016/j.bbrc.2008.09.086, 1:CAS:528:DC%2BD1cXhtlaqsLfJ
Pan Y Z, Morris M E, Yu A M. microRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol, 2009, 75: 1374–1379 19270061, 10.1124/mol.108.054163, 1:CAS:528:DC%2BD1MXmvVWqsbs%3D
Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol, 2008, 76: 582–588 18619946, 10.1016/j.bcp.2008.06.007, 1:CAS:528:DC%2BD1cXhtVSitbfN
38 Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther, 2008, 7: 2152–2159 18645025, 10.1158/1535-7163.MCT-08-0021, 1:CAS:528:DC%2BD1cXoslCnsr8%3D
Author information
Authors and Affiliations
Corresponding author
Additional information
Supperted by the National High Technology Research and Development Program of China (Grant No. 2006AA020704)
Rights and permissions
About this article
Cite this article
Wu, X., Xiao, H. miRNAs modulate the drug response of tumor cells. SCI CHINA SER C 52, 797–801 (2009). https://doi.org/10.1007/s11427-009-0114-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-009-0114-4